Numbrino (cocaine hydrochloride nasal solution) / Lannett - LARVOL DELTA

Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution and NUMBRINO™ Nasal Solution (clinicaltrials.gov) - P3 | N=40 | Recruiting | Sponsor: Noden Pharma | Not yet recruiting ➔ Recruiting | Phase classification: P4 ➔ P3 | N=20 ➔ 40 | Trial completion date: Dec 2021 ➔ Dec 2027 | Trial primary completion date: Sep 2021 ➔ Dec 2027

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Anesthesia • Otorhinolaryngology • Pediatrics

Pharmacokinetics, Safety, and Tolerability of GOPRELTO and NUMBRINO in Pediatric Nasal Procedures (clinicaltrials.gov) - P3 | N=40 | Not yet recruiting | Sponsor: Omnivium Pharmaceuticals LLC

New P3 trial • Anesthesia • Pediatrics

Topical Cocaine Hydrochloride Nasal Solution: Anesthetic and Surgical Considerations. (PubMed, Cureus) - "Despite this, the short latency, adequate duration of action, and inherent vasoconstrictive and decongestive capabilities make cocaine a valuable anesthetic agent for use in clinical procedures. As the relative benefit of using topical cocaine compared to the use of other vasoconstrictors and analgesics for nasal procedures remains undetermined in the current literature, this leaves the need for a comprehensive review of research that explores the risks and benefits of using topical cocaine in nasal procedures based on clinical trials that compare intranasal cocaine with various other analgesics and vasoconstrictors."

Journal • Review • Anesthesia • Hematological Disorders • Otorhinolaryngology • Pain

"$LCI LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO® AT SEYMOUR PLANT https://t.co/mrISRqdzvO #fdaapproval" (@stock_titan)

FDA event